Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.

Marina Natoli Klas HatjePratiksha GulatiFabian JunkerPetra HerzigZhiwen JiangIakov I DavydovMarkus GermannMarta TrübDaniel MarbachAdrian ZwickPatrick WeberStefan SeeberMark WieseDidier LardinoisViola Heinzelmann-SchwarzRobert RosenbergLothar TietzeKirsten D MertzPablo UmañaChristiane NeumannLaura Codarri-DeakHenry Kao Alfred Zippelius

Published in: Journal for immunotherapy of cancer (2022)

Our in vitro system reliably assessed responses to bispecific antibodies co-targeting PD-1 together with LAG-3 or TIM-3 using patients' tumor infiltrating immune cells and revealed transcriptional and phenotypic imprinting by bispecific antibody formats currently tested in early clinical trials.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
endothelial cells
newly diagnosed
chronic kidney disease
gene expression
prognostic factors
randomized controlled trial
transcription factor
cancer therapy
drug delivery
pluripotent stem cells
open label